MicroPort NeuroTech™ Completes First Implantations of NUMEN™ Coil Embolization System in Poland

Krakow/Kielce, Poland, 11 August 2022 — MicroPort Neurotech Limited (“MicroPort NeuroTech™”) recently announced that its independently developed Numen™ Coil Embolization System (“Numen™”) has been successfully used in the first two implantations in Poland. Numen™’s pushability and detachability were highly appreciated by the physicians.

The first two implantations were performed at Krakow University Hospital and Kielce Hospital, Poland. The first case was led by Prof. Popiela and Dr Brzegowy, on a female patient in her sixties who was diagnosed with unruptured ophthalmic segment aneurysms. The team decided to perform stent-assisted coil embolization using six NUMEN™ coils, all of which were successfully detached simultaneously. A follow-up examination demonstrated excellent recovery of the patient without any symptoms. In the second implant, the patient was initially diagnosed with unruptured basilar tip aneurysms. Dr Anteck and Dr Szylowski implanted six NUMEN™ coils, which yielded immediate and impressive results. Both teams agreed that NUMEN™ works well in filling the space and can achieve the desired localized packing density.

As a new-generation coil embolization system, NUMEN™ features stable embolization and dense packing. Its ultra-fine platinum–tungsten coil and the unique 3D structure offer a combination of flexibility and support which can minimize pressure on the aneurysm wall to ensure safe embolization. NUMEN™ is available in various lengths, allowing doctors to select the most appropriate coil for precise embolization based on each patient’s condition.

The NUMEN™ Coil Embolization System and NumenFR™ Coil Detachment System were approved for marketing in China in 2020. They have received EU CE Marking and marketing approvals from US FDA, Korea MFDS, and Brazil ANVISA, and their first overseas implantations were completed in 2021. In February 2022, NUMEN Silk™ 3D Electronically Detachable Coil Embolization System was approved by NMPA for marketing. The launch of this product line not only enriches MicroPort NeuroTech™’s product portfolio for hemorrhagic stroke treatment but also provides more clinical options that are safer and more effective.

Cerebral aneurysms are mostly abnormal bulges in the walls of intracranial arteries. The possibility of aneurysm rupture increases over time, and intracranial aneurysms are known as “time bomb in the head” due to their high mortality and morbidity rate upon rupture. Coil embolization is one of the most important methods of intracranial aneurysm treatment. The first two implantations of NUMEN™ in Poland signal the rapid penetration of MicroPort NeuroTech™ products into the EU market. In the future, MicroPort NeuroTech™ will continue to strengthen in-depth cooperation with overseas clinical experts and provide top-quality and more accessible and comprehensive medical solutions to stroke patients worldwide.

About MicroPort NeuroTech™

Founded in Shanghai in 2012, MicroPort NeuroTech Limited (“MicroPort NeuroTech™”, stock code: 02172.HK), a subsidiary of MicroPort Scientific Corporation (“MicroPort®”, stock code: 00853.HK), is a pioneer and largest Chinese company in the neuro-interventional medical device industry in China, dedicated to providing innovative solutions for physicians and patients. MicroPort NeuroTech™ has gradually entered the top 10 countries and regions for a number of neuro-interventional surgeries, including the United States, Europe, South Korea and Brazil. In the future, MicroPort NeuroTech™ will invest more resources in innovation and development to provide more high-quality and innovative cerebrovascular and neuro-interventions solutions for physicians and patients.

More information is available at www.medneurotech.com.